Lysophosphatidic acid accelerates the development of human mast cells

Blood

Volumn 104, Issue 13, 2004, Pages 4080-4087

  Bagga, Savita ^b   Price, Kursteen S ^b   Lin, Debby A ^b   Friend, Daniel S ^b   Austen, K Frank ^b   Boyce, Joshua A ^a  

^a Smith Research Bldg   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; GROWTH FACTOR; IMMUNOGLOBULIN E; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 9; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; RECEPTOR BLOCKING AGENT; STEM CELL FACTOR; UNCLASSIFIED DRUG; VPC 32179;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL HYPERPLASIA; CELL MATURATION; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IMMUNITY; MAST CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 10244227889     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-03-1166     Document Type: Article

References (54)

1. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature. 1996;381:75-77.
2. Ruitenberg EJ, Elgersma A. Absence of intestinal mast cell response in congenitally athymic mice during Trichinella spiralis infection. Nature. 1976;264:258-260.
3. Rodewald HR, Dessing M, Dvorak AM, Galli SJ. Identification of a committed precursor for the mast cell lineage. Science. 1996;271:818-822.
4. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature. 1988;335:88-89.
5. Ochi H, Hirani WM, Yuan Q, Friend DS, Austen KF, Boyce JA. T helper type-2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med. 1999;271:267-280.
6. Yanagida M, Fukamachi H, Ohgami K, et al. Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6, on the survival of cultured human mast cells. Blood. 1995;86:3705-3714.
7. Irani AM, Craig S, DeBlois G, Elson CO, Schechter NM, Schwartz LB. Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function. J Immunol. 1987;138:4381-4386.
8. Skopouli FN, Li L, Boumba D, et al. Association of mast cells with fibrosis and fatty infiltration in the minor salivary glands of patients with Sjogren's syndrome. Clin Exp Rheumatol. 1998;16:63-65.
9. Tsuneyama K, Kono N, Yamashiro M, et al. Aberrant expression of stem cell factor on biliary epithelial cells and peribiliary infiltration of c-kit-expressing mast cells in hepatolithiasis and primary sclerosing cholangitis: a possible contribution to bile duct fibrosis. J Pathol. 1999;189:609-614.
10. Benoist C, Mathis D. Mast cells in autoimmune disease. Nature. 2002;420:875-878.
11. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002;297:1689-1692.
12. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol. 2004;146:1-12.
13. Akoi J, Taira A, Takanezawa Y, et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem. 2002;277:48737-48744.
14. Tigyi G, Miledi R. Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells. J Biol Chem. 1992;267:21360-21367.
15. Goetzl EJ, Lee H, Azuma T, Stossel TP, Turck CW, Karliner JS. Gelsolin binding and cellular presentation of lysophosphatidic acid. J Biol Chem. 2000;275:14573-14578.
16. Goetzl EJ, Lee H, Dolerzalova H, et al. Mechanisms of lysolipid phosphate effects on cellular survival and proliferation. Ann N Y Acad Sci. 2000;905:177-187.
17. Hecht JH, Weiner JA, Post SR, Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol. 1996;135:1071-1083.
18. An S, Bleu T, Hallmark OG, Goetzl EJ. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem. 1998;273:7906-7910.
19. Bandoh K, Aoki J, Hosono H, et al. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem. 1999;274:27776-27785.
20. Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distinct from the Edg family. J Biol Chem. 2003;278:25600-25606.
21. Fukushima N, Ishii L, Contos JJ, Weiner JA, Chun J. Lysophospholipid receptors. Ann Rev Pharmacol Toxicol. 2001;41:507-534.
22. Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J. Requirement for the IpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci U S A. 2000;97:13384-13389.
23. Hooks SB, Santos WL, Im DS, Heise CE, Macdonald TL, Lynch KR. Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. J Biol Chem. 2001;276:4611-4621.
24. McIntyre TM, Pontsler AV, Silva AR, et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPAR-α agonist. Proc Natl Acad Sci U S A. 2003;100:131-136.
25. Goetzl EJ, Kong Y, Voice JK. Differential constitutive expression of functional receptors for lysophosphatidic acid by human blood lymphocytes. J Immunol. 2000;164:4996-4999.
26. Hornuss C, Hammermann R, Fuhrmann M, Juergens UR, Racke K. Human and rat alveolar macrophages express multiple EDG receptors. Eur J Pharmacol. 2001;429:303-308.
27. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273:25573-25580.
28. Cippitelli M, Fionda C, Di Bona D, et al. The cyclopentenone-type prostaglandin 15-deoxy-delta 12,14-prostaglandin J2 inhibits CD95 ligand gene expression in T lymphocytes: interference with promoter activation via peroxisome proliferator-activated receptor-gamma-independent mechanisms. J Immunol. 2003;170:4578-4592.
29. Nilsson G, Johnell M, Hammer CH, et al. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol. 1996;157:1693-1698.
30. Kambe N, Kambe M, Kochan JP, Schwartz LB. Human skin-derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes. Blood. 2001;97:2045-2052.
31. Heasley BH, Jarosz R, Lynch KR, Macdonald TL. Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett. 2004;14:2735-2740.
32. Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. J Biol Chem. 2004;279:8300-8315.
33. Irani AM, Bradford TR, Kepley CL, Schechter NM, Schwartz LB. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem. 1989;37:1509-1515.
34. 4 synthase expression by interleukin 4. J Exp Med. 2001;193:123-133.
35. Xiang Z, Nillson G. IgE receptor-mediated release of nerve growth factor by mast cells. Clin Exp Allergy. 2001;30:1379-1386.
36. Esposito I, Kleeff J, Bischoff SC, et al. The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab Invest. 2002;81:1481-1492.
37. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology. 2001;57:47-55.
38. Dahl C, Saito H, Neilsen HV, Schiotz PO. The establishment of a combined serum-free and serum-supplemented culture method of obtaining functional cord blood-derived human mast cells. J Immunol Methods. 2002;262:137-143.
39. Matsuzawa S, Sakashita K, Kinoshita T, Ito S, Yamashita T, Koike K. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol. 2003;170:3461-3467.
40. Matsumoto R, Sali A, Ghildyal N, Karplus M, Stevens RL. Packaging of proteases and proteoglycans in the granules of mast cells and other hematopoietic cells: a cluster of histidines on mouse mast cell protease 7 regulates its binding to heparin serglycin proteoglycans. J Biol Chem. 1995;270:19524-19531.
41. Goetzl EJ, Kong Y, Mei B. Lysophosphatidicacid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol. 1999;162:2049-2056.
42. Lai JM, Lu CY, Yang-Yen HF, Chang ZF. Lysophosphatidic acid promotes phorbol-ester-induced apoptosis in TF-1 cells by interfering with adhesion. Biochem J. 2001;359:227-233.
43. Idzko M, Laut M, Panther E, et al. Lysophosphatidic acid induces chemotaxis, oxygen radical production, CD11b up-regulation, Ca(2+) mobilization, and actin reorganization in human eosinophils via pertussis toxin-sensitive G proteins. J Immunol. 2004;172:4480-4485.
44. Sautin YY, Crawford JM, Svetlov SI. Enhancement of survival by LPA via Erk1/Erk2 and PI 3-kinase/Akt pathways in a murine hepatocyte cell line. Am J Physiol Cell Physiol. 2001;281:C2010-C2019.
45. Lu-Kuo JM, Fruman DA, Joyal DM, Cantley LC, Katz HR. Impaired kit- but not FcεRI-initiated mast cell activation in the absence of phosphoinositide 3-kinase p85α gene products. J Biol Chem. 2000;275:6022-6029.
46. Hu YL, Tee MK, Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst. 2001;93:762-768.
47. 2+/calmodulin- dependent protein kinase or epidermal growth factor receptor tyrosine kinase abolishes lysophosphatidic acid-mediated DNA-synthesis in human myometrial smooth muscle cells. Cell Biol Int. 2003;27:341-347.
48. 2 in lysophosphatidate-induced transactivation of platelet-derived growth factor receptor-beta in human branchial epithelial cells. J Biol Chem. 2003;278:39931-39940.
49. Lantz CS, Boesiger J, Song CH, et al. Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature. 1998;392:90-93.
50. Yeatman CF, Jacobs-Helber SM, Mirmonsef P, et al. Combined stimulation with the T helper cell type 2 cytokines interleukin (IL)-4 and IL-10 induces mouse mast cell apoptosis. J Exp Med. 2000;192:1093-1103.
51. Oskeritzian CA, Wang Z, Kochan JP, et al. Recombinant human (rh)IL-4-mediated apoptosis and recombinant human IL-6-mediated protection of recombinant human stem cell factor-dependent human mast cells derived from cord blood mononuclear cell progenitors. J Immunol. 1999;163:5105-5115.
52. Godfraind C, Louahed J, Faulkner L, et al. Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice. J Immunol. 1998;160:3989-3996.
53. Alexandrakis M, Letourneau R, Kempuraj D, et al. Flavones inhibit proliferation and increase mediator content in human leukemic mast cells (HMC-1). Eur J Haematol. 2003;71:448-454.
54. Siess W, Zangl K, Essler M, et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoproteins and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A. 1999;96:6931-6936.